home
Enter your email to join our mailing list:
 
FREE picks every Monday!
   
FAQs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
home
   
2008 HOTFLASH PICK DETAILS

HOTSHOTSTOCKS NEW PICKS Mon. November 10, 2008

Translate this page to:

 

Click here: Santarus Inc. Homepage

PICK: 11/10/08..........CLOSE: 2.64...........SUGGESTED STOP: 2.19

11.10.08 Up 0.13 (5.18%)

Corporate


We are a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians. Our current efforts are primarily focused on the commercialization of ZEGERID® (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension for the treatment of upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). ZEGERID was developed by us based on our proprietary, immediate-release proton pump inhibitor (PPI) technology (see Products for more information). In the U.S. prescription market, our commercial organization promotes our ZEGERID products to a targeted group of gastroenterologists and primary care physicians who accounted for writing prescriptions for approximately one-third of the $14 billion market for PPIs in 2007.

To further leverage our proprietary PPI technology and diversify our sources of revenue, we have entered into strategic alliances with two global pharmaceutical companies. In October 2006, we signed an exclusive license agreement with Schering-Plough Consumer Healthcare Products, Inc. (Schering-Plough) for over-the-counter (OTC) ZEGERID products in the U.S. and Canadian OTC markets. Schering-Plough submitted a New Drug Application to the U.S. Food and Drug Administration for an OTC ZEGERID branded product in March 2008. In December 2007, we announced a license agreement with Glaxo Group Limited, an affiliate of GlaxoSmithKline, plc (GSK), to develop prescription and OTC immediate-release omeprazole products in up to 114 countries including countries in Africa, Asia, the Middle-East, and Central and South America. We also signed a distribution agreement with GSK to sell ZEGERID prescription products in Puerto Rico and the U.S. Virgin Islands, and GSK launched ZEGERID Capsules and Powder for Oral Suspension in these territories in February 2008.

Our goal is to become a leading specialty pharmaceutical company. We plan to continue to seek to maximize the value of our PPI technology, as well as expand our product portfolio through co-promotion, licensing or acquisition of marketed or late stage proprietary products. In 2007 we reported total revenues of $94.4 million, compared to 2006 total revenues of $49.2 million. We reported a net loss in 2007 of $44.3 million, a decrease of 22% compared with the prior year. Our stock trades on the NASDAQ Global Market under the symbol "SNTS".

Management

Our management team has substantial experience in product development, manufacturing, clinical development, regulatory affairs and sales and marketing through their participation at other companies in the successful development and commercialization of GI products.

 

Senior Management

Gerald T. Proehl
President, Chief Executive Officer and Director
Gerald T. Proehl has served as our President and Chief Executive Officer and as a director since January 2002. From March 2000 through December 2001, Mr. Proehl was our President and Chief Operating Officer. From April 1999 to March 2000, Mr. Proehl was our Vice President, Marketing and Business Development. Prior to joining Santarus, Mr. Proehl was with Hoechst Marion Roussel, Inc., a global pharmaceutical company, for 14 years, where he served in various capacities in multiple therapeutic areas including gastrointestinal, cardiovascular, wound care and central nervous system, and from March 1997 to April 1999 served as Vice President of Global Marketing. While at Hoechst Marion Roussel, Mr. Proehl oversaw the co-promotion of the proton pump inhibitor Prilosec® by Hoechst Marion Roussel and Astra Merck Inc. and was responsible for the marketing of gastrointestinal products Carafate® and Pentasa®, among products in several other therapeutic areas. Mr. Proehl holds a B.S. in education from the State University of New York at Cortland, an M.A. in exercise physiology from Wake Forest University and an M.B.A. from Rockhurst College.


E. David Ballard II, M.D.
Senior Vice President, Clinical Research and Medical Affairs
E. David Ballard II, M.D. joined Santarus in March 2004 as Vice President, Clinical Research, was appointed Vice President, Medical Affairs in September 2005 and was promoted to Vice President, Clinical Research and Medical Affairs in March 2006. From March 2000 to February 2004, Dr. Ballard served in various positions at TAP Pharmaceutical Products Inc., a pharmaceutical company, most recently serving as Therapeutic Area Head, Gastroenterology and Internal Medicine. From July 1997 to March 2000, Dr. Ballard was a Medical Director at Abbott Laboratories, a pharmaceutical company. Dr. Ballard holds a B.S. in biology from Morehouse College and an M.D. from the Medical College of Ohio. Dr. Ballard is also certified as a gastroenterologist by the American Board of Internal Medicine.


Debra P. Crawford
Senior Vice President, Chief Financial Officer, Treasurer and Secretary
Debra P. Crawford joined Santarus in November 2000 as Vice President, Chief Financial Officer, Treasurer and Secretary and was promoted to Senior Vice President, Chief Financial Officer, Treasurer and Secretary in December 2003. Prior to joining Santarus, Ms. Crawford served as Vice President, Chief Financial Officer and Treasurer from July 1998 to May 2000 for Women First HealthCare, Inc., a specialty healthcare company. Ms. Crawford was also Assistant Secretary of Women First from July 1998 to February 1999 and Secretary from March 1999 to May 2000. From May 2000 to October 2000 and from March 1997 to August 1998, Ms. Crawford was self-employed and provided financial consulting services in the area of corporate development and in the capacity of acting chief financial officer. Ms. Crawford also served as Chief Financial Officer, Vice President of Finance and Administration and Treasurer of IVAC Holdings, Inc. from January 1996 to December 1996 and of IVAC Medical Systems, Inc., a medical device company, from January 1995 to December 1996. From September 1981 to December 1994, Ms. Crawford served in various financial positions within companies of the medical device division of Eli Lilly & Company. Ms. Crawford is a certified public accountant and holds a B.S. in business administration from San Diego State University.


Julie A. DeMeules
Senior Vice President, Human Resources
Julie A. DeMeules joined Santarus in January 2004 as Vice President, Human Resources and was promoted to Senior Vice President, Human Resources in February 2006. From January 2000 to November 2003, Ms. DeMeules served as Vice President, Human Resources at Quidel Corporation, a manufacturer and distributor of medical diagnostic products. From February 1991 to January 2000, Ms. DeMeules was employed with Advanced Tissue Sciences, a biotechnology company, most recently serving as Vice President, Human Resources. Prior to joining Advanced Tissue Sciences, Ms. DeMeules served as Director of Human Resources at Square D Corporation, a provider of electrical products, from June 1990 to February 1991. Prior to joining Square D Corporation, Ms. DeMeules served for several years as Vice President of Human Resources of Signet Armorlite, Inc., a manufacturer and distributor of ophthalmic lenses and supplies. Ms. DeMeules holds a B.A. in business administration from the University of San Diego and an M.B.A. from San Diego State University.


William C. Denby, III
Senior Vice President, Commercial Operations
William C. Denby, III joined Santarus in February 2002 as Senior Vice President, Commercial Operations. Prior to joining Santarus, from October 2001 to February 2002, Mr. Denby served as Senior Vice President of Commercial Operations of Agouron Pharmaceuticals, Inc., a provider of HIV and other specialty pharmaceutical products that was acquired by Pfizer Inc. From June 1997 to October 2001, Mr. Denby served as Senior Vice President and Vice President of Sales and Marketing for Agouron. From January 1995 to June 1997, Mr. Denby served as Senior Director of Sales and Marketing and Senior Director, Commercial and Marketing Affairs for Agouron. Prior to that, Mr. Denby was at Marion Laboratories for 18 years, holding various positions in corporate finance, strategic planning, and sales and marketing. While at Marion Laboratories, Mr. Denby was responsible for promoting a diverse product line which included brands such as Cardizem®, Nicorette® and the duodenal ulcer drug Carafate, and he helped secure managed care formulary acceptance for these products. Mr. Denby holds a B.A. in English from the State University of New York at Fredonia and an M.B.A. from Rockhurst College.


Carey J. Fox, J.D.
Senior Vice President, General Counsel
Carey J. Fox joined Santarus as Senior Director, Legal Affairs in March 2002, served as Vice President, Legal Affairs from May 2004 to February 2006 and was promoted to Vice President, General Counsel in March 2006. Prior to joining Santarus, Ms. Fox served as Director, Legal Affairs for Elan Pharmaceuticals, Inc., a pharmaceutical company, from January 2002 to March 2002. Prior to joining Elan, Ms. Fox was associated with the law firm of Brobeck, Phleger & Harrison LLP from May 1998 to December 2001 and with the law firm of Fennemore Craig from January 1996 to May 1998, where she represented a variety of clients in general corporate and securities law matters. Ms. Fox is a member of the State Bar of California and holds a B.A. in social ecology from the University of California, Irvine and a J.D. from Arizona State University.


Warren E. Hall
Senior Vice President, Manufacturing and Product Development
Warren E. Hall joined Santarus in July 2001 as Vice President, Manufacturing and Product Development and was promoted to Senior Vice President, Manufacturing and Product Development in December 2003. Prior to joining Santarus, Mr. Hall served as Senior Director of Development from July 2000 to July 2001 at Dura Pharmaceuticals, a specialty pharmaceutical company that was acquired by Elan Corporation, plc, a pharmaceutical company. Mr. Hall served as Senior Director of Program Management for the pulmonary group at Dura from February 1999 to July 2000, and as Senior Director of Manufacturing from July 1998 to February 1999. From November 1995 to June 1998, Mr. Hall served as Director of Manufacturing Operations at Cell Therapeutics, Inc., a cancer treatment company. Prior to Cell Therapeutics, Mr. Hall was with Mallinckrodt, Inc., a pharmaceutical and specialty chemical company, for 17 years, serving in various capacities, most recently as Director of Worldwide Manufacturing. Mr. Hall holds a B.A. in chemistry and biology from Greenville College and an M.S. in organic chemistry from Southern Illinois University.


Michael D. Step
Senior Vice President, Corporate Development
Michael D. Step joined Santarus as Senior Vice President, Corporate Development in February 2005. Prior to joining Santarus, he served from August 2000 to February 2005 with Amylin Pharmaceuticals, Inc., a biopharmaceutical company, most recently as Vice President, Corporate Development. In this capacity, he was responsible for leading corporate development activities, including product licensing, strategic planning, and mergers and acquisitions evaluations. Prior to Amylin, he was Senior Director, Business Development at Dura Pharmaceuticals, Inc., a pharmaceutical company, from May 1998 to July 2000. In this position, his duties included licensing of marketed pharmaceutical products. Prior to that, he served in corporate development and strategic planning at Hoffmann-La Roche and sales and management roles at Roche Labs and Syntex Labs. Mr. Step holds a B.A. in political science from Vanderbilt University and an M.B.A. from the University of Southern California.



Maria Bedoya-Toro, PhD
Vice President, Regulatory Affairs and Quality Assurance
Maria Bedoya-Toro, PhD joined Santarus in May 2007 as Vice President, Regulatory Affairs and Quality Assurance. She previously served as Senior Director Regulatory Affairs at Eisai Medical Research Inc. from November 2006 to May 2007, moving to Eisai from Ligand Pharmaceuticals, Inc. when Ligand divested their oncology products to Eisai in November 2006. Dr. Bedoya-Toro worked as Senior Director Global Regulatory Affairs and Compliance at Ligand from 2003 to 2006. From 2000 to 2003 she served as Director Global Regulatory Affairs at Baxter Hyland Immuno. From 1998 to 2000 Dr. Bedoya-Toro worked at BASF Bioresearch Corporation as Director Regulatory Affairs/Quality, and from 1996 to 1998 she worked as Director Quality Assurance and Regulatory Compliance at Amylin Pharmaceuticals. From 1988 to 1996 Dr. Bedoya-Toro worked at Rhone-Poulenc Rorer in a number of positions of increasing responsibility in regulatory compliance, quality assurance, quality control and compliance. Dr. Bedoya-Toro holds an M.B.A from the University of Chicago and a Ph.D. in bio-analytical chemistry from Ohio University. In addition she holds an M.A. in bio-analytical chemistry and a B.S. in chemistry from Western Michigan University.


Blake A. Boland
Vice President, Sales
Blake A. Boland has served as Vice President, Sales since July 2004 and previously served as Director, National Sales beginning in January 2004. Prior to joining Santarus, Mr. Boland was with Aventis Pharmaceuticals, a global pharmaceutical company, for 16 years. From November 1998 to December 2003, Mr. Boland served as a Regional Sales Director, where he was responsible initially for building a new primary care sales organization in the western U.S. During his career with Aventis and predecessor companies, Mr. Boland held various positions in sales, marketing and sales management in such therapeutic areas as gastroenterology, cardiovascular, respiratory, diabetes and anti-infectives. Mr. Boland holds a B.A. in business administration from Graceland College and an M.B.A. from Rockhurst College.


Jonathan M. Hee
Vice President, Commercial Affairs
Jonathan M. Hee joined Santarus in January 2004 as Vice President, Commercial Affairs. From October 2000 to December 2003, Mr. Hee served as Vice President, Sales and Marketing Services at Agouron Pharmaceuticals, Inc., a provider of HIV and other specialty pharmaceutical products that was acquired by Pfizer Inc. From October 1996 to October 2000, Mr. Hee served as Director and Senior Director, Sales and Marketing Services for Agouron. Mr. Hee was a Senior Manager of Segment Marketing for Agouron from November 1995 to October 1996. Prior to joining Agouron, Mr. Hee was with Gensia Inc., a cardiovascular and multi-source injectable drug company, where he held various management roles including Associate Director positions in marketing and market planning. Mr. Hee holds a B.S. in chemical engineering from Stanford University and an M.B.A. from Harvard University.


Martha L. Hough
Vice President, Finance and Investor Relations
Martha L. Hough joined Santarus in January 2005 as Vice President, Finance and Investor Relations. From August 2002 to December 2004, and September 1998 to October 1999, Ms. Hough was a self-employed consultant to medical technology and pharmaceutical companies. From November 1999 to July 2002, Ms. Hough was Vice President, Business Development, and Chief Financial Officer of LMA North America, Inc., a profitable private medical device company. From 1987 to 1998, Ms. Hough worked in various finance, investor relations, and marketing positions at Gensia Sicor, Inc., serving as Vice President, Finance and Corporate Communications there from January 1995 to June 1998. Ms. Hough holds a B.S. in psychology from Colorado State University and an M.B.A. from the Tuck School of Business at Dartmouth College.


Thomas J. Joyce
Vice President, Marketing and National Accounts
Thomas J. Joyce joined Santarus in January 2004 as Vice President, Marketing and National Accounts. From April 2002 to January 2004, Mr. Joyce served as Senior Director, Marketing at Neurocrine Biosciences, Inc., a drug discovery and development company. From July 1999 to March 2002, Mr. Joyce served as Senior Director, Global Marketing Planning of Agouron Pharmaceuticals, Inc., a provider of HIV and other specialty pharmaceutical products that was acquired by Pfizer Inc. From September 1997 to June 1999 and from May 1996 to August 1997, Mr. Joyce served as Associate Director of Corporate Development and Senior Market Manager, respectively, of Agouron. Prior to joining Agouron, Mr. Joyce held various sales and sales management positions at Hoechst Marion Roussel. Mr. Joyce holds a B.A. in psychology from the University of Dayton.

Mission & Values

Mission

To become a leading specialty pharmaceutical company that acquires, develops and commercializes proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Values

We believe our success begins with our employees. We foster a work environment where ideas are encouraged and a passion for excellence is shared. We move fast, accomplish much and have fun doing it.

We actively live by our core values:

Teamwork - Working together to achieve a common goal in a mutually dependent way

  • Support group goals over self-interest
  • Consider the impact of our decisions on others; seek input and share information
  • Align project and functional team activities
Ownership - Assume personal responsibility for Santarus' goals, resources, challenges and opportunities
  • Be accountable
  • Identify solutions, not just the problem
  • Take the initiative
Productivity - Adopt a strong results orientation and emphasize the achievement of goals and objectives
  • Focus and prioritize to add value and deliver results
  • Demonstrate a sense of urgency
Integrity - Conducting business responsibly through the decisions we make and the actions we take
  • Do what you say you will do. Be reliable.
  • Treat others with respect
  • Perform with fairness, consistency and impartiality
Quality - We consistently meet or exceed the expectations of both internal and external customers
  • Seek out and implement best practices
  • Set high standards for ourselves by being clear, accurate, thorough, and timely
  • Practice continuous improvement

Investor Relations
Webcast Image Webcast
Q3 2008 Santarus, Inc. Earnings Conference Call (Replay)
11/03/08 at 5:00 p.m. ET
Webcast Image Webcast
Santarus, Inc. at Rodman & Renshaw Annual Global Investment Conference (Live)
11/12/08 at 9:55 a.m. ET
Santarus, Inc. at Rodman & Renshaw Annual Global Investment Conference
Wednesday, November 12, 2008 9:55 a.m. ET  
Webcast PresentationHelp Help
Listen to the Webcast in Windows Media Player Listen to the Webcast in Real Player  Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

 


Contact

 

Santarus Inc.
3721 Valley Centre Drive
Suite 400
San Diego, CA 92130
United States - Map
Phone: 858-314-5700
Fax: 858-314-5701
Web Site: http://www.santarus.com
 


Click here: GeoResources, Inc. Homepage

 

PICK: 11/03/08..........CLOSE: 12.95...........SUGGESTED STOP: 12.74

PROFILE

Through its subsidiaries G3 Operating, LLC and Southern Bay Operating, LLC, GeoResources, Inc. owns and operates producing oil and gas properties in the Gulf Coast, Permian Basin, Rocky Mountains and Williston Basin in the U.S. and conducts oil and gas exploration and development and production operations in these areas.

At year-end 2007, GeoResources’ pro forma reserves are currently estimated at 15.7 million barrels of oil equivalent, approximately 69% oil and 85% proved developed. Production at year end was about 2,165 BOPD and 8,620 Mcfd. The Company owns 145,780 net developed acres and 59,149 net undeveloped acres in Texas, Louisiana, Colorado, North Dakota, Montana and Utah.

STRATEGY

GeoResources’ business strategy includes the acquisition of oil and gas reserves, along with field re-engineering, development, exploitation and exploration activities, intended to increase estimated quantities of proved reserves, and increase production and share values.

In implementing its strategy, management seeks to increase oil and gas production volumes, lower per-unit operating expenses, and thereby increase cash flow and operating net income. The Company operates in three core oil and gas areas; the Gulf Coast of Texas and Louisiana, the Rocky Mountain region of Colorado and Wyoming and the Williston Basin in North Dakota and Montana. GeoResources manages its Gulf Coast operations through its Southern Division headquarters in Houston. Activities in the Rocky Mountains and the Williston Basin are administered from the Northern Division headquarters in Denver.

Initially GeoResources expects to continue, and in some instances accelerate, development of existing properties. Management further intends to expand its portfolio of oil and gas properties in both the Southern and Northern Divisions to include producing reserves that generate current cash flow and net income and  exploration and development opportunities that can significantly increase reserves and production. GeoResources may solicit industry partners and institutional investors into acquisition, development or exploration projects, on a promoted basis, in order to diversify and stay within capital budgets and earn carried or reversionary interests, in addition to its direct ownership. This should lower GeoResources acquisition, finding and development costs and may generate operating or management fee income to offset overhead.     

Separately or in connection with acquisition opportunities, exploration opportunities will be explored, and, where appropriate, drilled, with industry partners or institutional investors being solicited for higher risk prospects on a promoted basis.  GeoResources will emphasize prospects it originates or generates internally and can operate, but may also participate with selected independent oil and gas companies on a non-operated basis.  Projects may include, individually or in tandem, acquisitions, workovers, re-completions, development drilling and other developmental activities such as secondary recovery, prospect participation and exploration.  Management believes that a strategy involving a combination of acquisition, re-engineering, development and exploration activities is the preferable strategy to build shareholder value.  
  
Acquisitions and Divestitures

Acquisitions.  The acquisition focus is expected to be on oil and gas properties with the potential for meaningful economic returns resulting from the application of operational and technical attention, development of non-producing proved reserves and realization of exploration potential. Acquired interests will generally have the characteristics of manageable risk, predictable production and value enhancement potential.

Divestitures.  An ongoing part of the business strategy will to be to divest existing or acquired assets for cash or on a tax-free exchange basis where such assets do not have adequate “upside” potential, are staff intensive or costly to operate in relation to production, are geographically separated from major operations or have other characteristics which are not compatible with the stage of the company’s operations.  Divestitures are an active part of any acquisition and any asset high-grading program.

Development Activities

An ongoing part of the business strategy will be to focus on development and exploitation of non-producing reserves through re-engineering activities such as installing down-hole and surface equipment, installing salt-water disposal wells, well workovers and recompletions, infill and development drilling (conventional and horizontal), secondary recovery and other related projects.  Operations, engineering and geological expertise with emphasis on cost control will be important to this part of the program.  The risks associated with development drilling are greater than operating and owning producing oil and gas, but more moderate than exploration activities.  In connection with field-wide development activities, typically comprehensive operations and reservoir engineering reviews will be made and integrated with geological and geophysical studies, to define development opportunities.  A development plan and capital budget can then be implemented.  The use of 3-D seismic technology and computer aided engineering systems will typically be utilized to recover bypassed or undeveloped reserves.  Management believes the combined entity will have the required technical systems and personnel to successfully evaluate and develop non-producing reserves in its areas of operations.  

Exploration

Exploration activities will focus on acquired properties or company generated prospects.  This part of the strategy has two distinct purposes: 1) to develop acquisitions fully, and 2) to realize substantive returns from exploration.  All acquisitions will be thoroughly evaluated for exploration potential through the review of available technical data, including well control, seismic, production, pressure and other data.  Where applicable, 3-D seismic imaging may be acquired or shot to further define opportunities.  GeoResources will actively drill and/or promote such opportunities to industry partners.  As the geological objectives move to a higher risk profile, industry partners will be solicited on a promoted basis.  

While exploration expenditures may not comprise a large part of the Company’s capital commitment, these activities are an important and integral part of the business strategy.  Financial returns can be enhanced and risk can be mitigated by generating or participating in prospects prior to sale to industry partners; that is, developing the prospect to a point where the combined entity will retain a direct working interest and a portion of the prospect can be sold to industry partners for a “front-end” cash profit and an additional promoted interest, such as an overriding royalty interest, carried interest or back-in-after payout.

Corporate Mergers and Acquisitions

GeoResources management has substantial merger and acquisition experience. This capability is enhanced by relationships with investment and commercial bankers, institutional investors, brokers and principals.  Management intends to actively pursue merger and acquisition opportunities with other private and public oil and gas companies.  If any such opportunities become available, acquisition or merger criteria would include, but not be limited to: (1) the potential for growth in a core area; (2) the opportunity to increase current cash flow; (3) development and exploration potential; (4) the ability to refinance debt at lower cost of capital; (5) realization of administrative savings; and (6) an opportunity to realize value of proved assets and prospects.

OFFICERS

Frank A. Lodzinski - Chief Executive Officer & President, age 57, has over 35 years of oil and gas industry experience. In 1984, he formed Energy Resource Associates, Inc., which acquired management and controlling interests in oil and gas limited partnerships, joint ventures and producing properties. Certain partnerships were exchanged for common shares of Hampton Resources Corporation in 1992, which Mr. Lodzinski joined as a director and President. Hampton was sold in 1995 to Bellwether Exploration Company for $35 million. In 1996, he formed Cliffwood Oil & Gas Corp. and in 1997, Cliffwood shareholders acquired controlling interests in Texoil, Inc. In 2001, Texoil, Inc. was sold to Ocean Energy, Inc. for $135 million. In 2001, Mr. Lodzinski was appointed CEO and President of AROC, Inc. In 2003, AROC Inc. completed a $71 million monetization with an institutional investor and began a plan of liquidation in 2004. As part of that liquidation, Mr. Lodzinski was responsible for and oversaw petitions for liquidation under Federal bankruptcy laws, of two AROC Inc. subsidiaries, Latex Petroleum Corporation, an Oklahoma corporation and Source Petroleum Inc., a Louisiana corporation. In 2004, Mr. Lodzinski formed Southern Bay Energy, LLC, the General Partner of Southern Bay, which acquired the residual assets of AROC, Inc., and he has served as President of Southern Bay Energy LLC since its formation. He is a certified public accountant and holds a BSBA degree in Accounting and Finance from Wayne State University in Detroit, Michigan.

Collis P. Chandler, III - Chief Operating Officer and Executive VP, Northern Region, age 38, has been President and sole owner of Chandler Energy, LLC since its inception in July 2000. From 1988-2000, Mr. Chandler served as Vice President of The Chandler Company, a privately-held exploration company operating primarily in the Rocky Mountains. His responsibilities over the 12-year period included involvement in exploration, prospect generation, acquisition, structure and promotion as well as direct responsibility for all land functions including contract compliance, lease acquisition and administration. Mr. Chandler received a Bachelor’s of Science degree from the University of Colorado, Boulder in 1992.

Robert J. Anderson - VP Business Development, Acquisitions & Divestitures, age 44, is a Petroleum Engineer with 19 years of diversified domestic and international experience with both major oil companies (ARCO International / Vastar Resources) and independent oil companies (Hunt Oil / Hugoton Energy / Anadarko Petroleum). From October 2000 through February 2004, he was employed by Anadarko Petroleum Corporation as a petroleum engineer. From March 2004 through December 2004 he was employed by AROC, Inc. as Vice President, Acquisitions and Divestitures. He joined Southern Bay Energy, LLC in January 2005 as Vice President, Acquisitions and Divestitures. His professional experience includes acquisition evaluation, reservoir and production engineering and field development, and project economics, budgeting and planning. Mr. Anderson’s domestic acquisition and divestiture experiences include Gulf Coast Texas and Louisiana (offshore and onshore), east and west Texas, north Louisiana, Mid-Continent and the Rockies. His international experience includes Canada, South America and Russia. He has an undergraduate degree in Petroleum Engineering from the University of Wyoming (1986) and also holds an MBA, Corporate Finance, from the University of Denver (1988).

Howard E. Ehler - Chief Financial Officer, age 62, was employed as Vice President and Chief Financial Officer of AROC, Inc. from May 2001 through December 2004. Since January 2005, Mr. Ehler has been employed by Southern Bay Energy, LLC as Vice President and Chief Financial Officer. He previously served as Vice-President of Finance and Chief Financial Officer for Midland Resources, Inc. from March 1997 through October 1998. From November 1999 through April 2001 he performed independent accounting and auditing services in oil and gas as a sole practitioner in public accounting. He was employed in public accounting with various firms for over 21 years, including practice with Grant Thornton, where he was admitted to the partnership. He has substantive experience in oil and gas banking, finance accounting and reporting. In addition, his experience includes partnership administration, tax, budgets and forecasts and cash management. Mr. Ehler holds an Accounting degree from Texas Tech University (1966) and has been a certified public accountant since 1970.

Francis M. Mury - Chief Operating Officer and Executive VP, Southern Region, age 55, has been active in the oil and gas industry since 1974. He was employed by AROC, Inc. as Executive Vice President from May 2001 through December 2004. Since January 2005, he has been employed by Southern Bay Energy LLC as Executive Vice President. Mr. Mury worked for Texaco, Inc. from July 1974 through March 1979, ending his tenure there as a petroleum field engineer. From April 1979 through December 1985, he worked for Wainoco Oil & Gas as a production engineer and drilling superintendent. From January 1986 to November 1989 he worked for Diasu Oil & Gas as an operations manager. He has worked with Mr. Lodzinski since 1989, including Hampton Resources Corporation, where he served as Vice-President-Operations from January 1992 through May 1995, and Texoil, Inc. where he served as Executive Vice President from November 1997 through February 2001. His experience extends to all facets of petroleum engineering, including reservoir engineering, drilling and production operations and further into petroleum economics, geology, geophysics, land and joint operations. Geographical areas of experience include the Gulf Coast (offshore and onshore), East and West Texas, Mid-Continent, Florida, New Mexico, Oklahoma, Wyoming, Pennsylvania and Michigan. Mr. Mury received a degree in Computer Science (1974) from Nicholls State University, Thibodeaux, Louisiana.

Jeffrey P. Vickers - VP of Exploration & Development, age 53, received a Bachelor of Science degree in Geological Engineering with a Petroleum Engineering option from the University of North Dakota in 1978. In 1979, Mr. Vickers joined Amerada Hess Corporation as an Associate Petroleum Engineer in the Williston Basin. In 1981, Mr. Vickers was employed by GeoResources as the Drilling and Production Manager where he was responsible for providing technical assistance and supervision of drilling and production operations and generated development drilling programs. He has served as President of GeoResources since January 1, 1983 and as a director of GeoResources since June 1982.

Cathy Kruse - Investor Relations, age 51, serves as Corporate Secretary for GeoResources, Inc. Ms. Kruse previously served as Secretary and business office manager and as a Director of GeoResources, Inc.  Mrs. Kruse graduated from the Atlanta College of Business in 1977 and was employed as a Legal Assistant for four years prior to her employment with us in May 1981. Mrs. Kruse serves on the North Dakota Governor’s Council for Workforce Development and serves on the Board of Directors for the North Dakota Chamber of Commerce.

OPERATIONS

Click Map to View Full Screen

(Click for Partnership Properties Map)


PRESS RELEASES

 
08/12/08

GeoResources, Inc. Provides Operations Update
Continues successful horizontal drilling in Texas and North Dakota

 
08/11/08

GeoResources, Inc. Reports Second Quarter and Six-Months Financial Results
   
06/26/08

GeoResources, Inc. Reports Second Quarter and
 Six-Months Financial Results
   
06/06/08

GeoResources, Inc. Announces Private Placement

   
06/02/08 GE unit and GeoResources investing $91 million in Oklahoma oil and gas reserves
   
05/12/08

GeoResources, Inc. Reports First Quarter Financial Results
   
05/01/08

GeoResources, Inc. Provides Operations Update Reports successful horizontal drilling in Texas and North Dakota

   
03/31/08 GeoResources Inc. Reports Year End, 4th Quarter and Annual Financial Results
   
02/21/08 GeoResources, Inc. Files Operations Update Form 8-K
   
02/15/08

GeoResources, Inc. Increases 2008-2009 Capital Budget

   
02/05/08 GeoResources, Inc. Announces Property Acquisition and Provides Operations Update

CONTACT


 


CONTACT

Denver

GeoResources, Inc.
G3 Operating, LLC
475 Seventeenth Street, Suite 1210
Denver, CO 80202
Phone: 303-297-2028
Fax: 303-297-2196

Click Here for a Map of Our Location

Houston

GeoResources, Inc.
Southern Bay Energy
110 Cypress Station Dr., Ste 220
Houston, TX 77090
Phone: 281-537-9920
Fax: 281-537-8324Web Site: http://www.georesourcesinc.com

Click Here for a Map of Our Location

 

Contact:

  • Cathy Kruse, Investor Relations (701) 572-2020

 
 

PICK: 10/27/08..........CLOSE: 7.22...........SUGGESTED STOP: 6.38


Click here for Questcor Pharmaceuticals, Inc. Homepage


Questcor Pharmaceuticals, Inc.(Nasdaq: QCOR) Questcor is a specialty pharmaceutical company focused on providing prescription drugs for central nervous system (CNS) disorders. We are presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. We will seek to develop and commercialize our own proprietary products, and are open to a range of partnering concepts in order to leverage our assets and build our portfolio

Management

Don M. Bailey
President and Chief Executive Officer


Steve Cartt
Executive Vice President, Corporate Development

Steven Halladay, Ph.D.
Senior Vice President, Clinical and Regulatory Affairs


Dave Medeiros
Senior Vice President, Pharmaceutical Operations


Gary Sawka
Senior Vice President of Finance and Chief Financial Officer


Timothy O'Neill, Ph.D.
Vice President, Contract Manufacturing


Eldon Mayer
Vice President, Commercial Operations

Board of Directors


Virgil D. Thompson, Chairman

Don M. Bailey

Neal C. Bradsher

Stephen C. Farrell

David Young

Corporate Mission


Questcor Pharmaceuticals, Inc. develops and commercializes novel CNS-focused therapeutics which address significant unmet medical needs. Our primary goal is to provide products that help improve the lives of patients with CNS disorders, and by doing this successfully we will build long term value for our shareholders.

Collaborations

  • Rigel

    Rigel licensed exclusive rights to research, develop and commercialize products utilizing proprietary Questcor antiviral technology.

Products

 

.........

About H.P. Acthar® Gel (repository corticotropin injection)
  • H.P. Acthar Gel (repository corticotropin injection) is natural source ACTH (adrenocorticotropic hormone) in 16% gelatin to provide a prolonged release after intramuscular or subcutaneous injection.
  • H.P. Acthar Gel may be used in the treatment of acute exacerbations of multiple sclerosis. In the treatment of acute exacerbations of multiple sclerosis daily intramuscular doses of 80-120 units for 2-3 weeks may be administered. Your healthcare provider will determine the specific dosage that is best for you.
  • H.P. Acthar Gel is also indicated for diagnostic testing of adrenocortical function.
  • H.P. Acthar Gel delivers efficacy comparable to high-dose IV steroids. However, with H.P. Acthar Gel, patients do not need physicians to perform IV administration.

 

Welcome to DoralForSleep.com

Many Americans have trouble falling asleep and staying asleep each night.

Doral® (quazepam tablets, USP) is a unique and highly effective sleep aid that has a low incidence of side effects.1,2

If you are experiencing sleep problems, it’s time to talk to your doctor about your treatment options. Doral may be right for you.

Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

Doral has been classified as a Schedule IV controlled substance.

Patients receiving Doral should be cautioned about possible combined effects with alcohol and other CNS depressants.

Please see full prescribing information and patient Medication Guide.

The product information provided in this site is intended only for residents of the United States.

References: 1. Kales A. Quazepam: hypnotic efficacy and side effects. Pharmacotherapy. 1990;10(1):1-12. 2. Doral [package insert]. Union City, Calif: Questcor Pharmaceuticals, Inc.: March 2006.
Doral is under license from Baker Norton Pharmaceuticals Inc.
Questcor is a registered trademark of Questcor Pharmaceuticals, Inc.

Recent News

 

Investor Relations


 

 

Contact


Questcor Pharmaceuticals, Inc.
3260 Whipple Road
Union City, CA 94587
United States - Map
Phone: 510-400-0700
Fax: 510-400-0799
Web Site: http://www.questcor.com



 
 
 

PICK: 10/20/08..........CLOSE:....13.35.......SUGGESTED STOP: 11.66


Click here for Nevada Chemicals Inc. Homepage


Nevada Chemicals Inc. (Nasdaq: NCEM) Welcome to Nevada Chemicals, the premier producer of strategic chemicals for the gold mining industry of the United States.

Nevada Chemicals is headquartered in Salt Lake City, Utah and its shares trade on the Nasdaq market under the symbol NCEM. We are strategically located to produce and deliver liquid sodium cyanide to Western U.S. based precious metal mining concerns. We have established a partnering relationship with the mines to provide products delivered on responsible care principles with emphasis on safety for the public, the environment and our own employees. We take great pride in the safe and productive record we have established over the last 12 years.

Nevada Chemicals' primary objective is to grow into the cyanide provider of choice through the continual enhancement of shareholder value. The company consistently produces high rates of return on equity and capital, profits and strong cash flows providing for long-term growth.

Nevada Chemicals holds a 50% stake in Cyanco, a chemical producer of sodium cyanide located in Winnemucca, Nevada. Cyanco is the leading provider of liquid sodium cyanide to the gold mining operations in Nevada and has a capacity to produce in excess of 85 million pounds per year. Nevada Chemicals, with our partner Degussa Corporation, has recently expanded the business of Cyanco by purchasing the sodium cyanide distribution business of FMC Corporation.

Nevada Chemicals, Inc. is a producer of mining chemicals and services with a successful record of developing and operating chemical businesses since 1979, when it was Mining Services International (MSI):

• Successfully conceived, constructed, developed and operated Cyanco, the major producer of liquid sodium cyanide in the United States. Cyanco is a joint venture operation with Degussa Corporation, and continually operates as a model of safety and efficiency.

• Developed and marketed technology which has been used and licensed throughout the world in the field of explosives and cyanide processing.

• Pioneered bulk explosive systems throughout the world through MSI, having successfully operated in over 12 countries.

• Successfully sold the explosives division to UEE of Spain.

• Established joint ventures in several major mining districts in the world to produce cyanide and explosives.

• Developed grass roots production facilities throughout the world.

THE NEW NEVADA CHEMICALS

Past to Present

Nevada Chemicals was formed as Mining Services International (MSI) in 1979 as a provider of chemical products and services to the mining industry. MSI entered the industry providing bulk mining explosives. By the late 1980's it expanded to other mining chemicals and began production of Sodium Cyanide through its Joint Venture, Cyanco, near Winnemucca, Nevada. In late 2001, MSI sold the explosives division to a Spanish company UEE and transitioned into a new company, Nevada Chemicals, Inc. (NCI) which trades on NASDAQ as NCEM.

Over the years NCI has exercised a strategy to become the largest provider of sodium cyanide to the gold mining industry operating in the United States. This successful strategy is based upon providing quality products with extraordinary service to its customers through state-of-the-art facilities and proactive management. NCI/MSI has successfully developed new technology and has licensed its technology into several significant mining areas of the world including Australia, South Africa, Namibia and Chile and provided products to large coal mines in the Western United States.

In 1983, NCI (as MSI) became a public company by merging with Rocky Mountain Natural Resources, a company involved in leasing oil and gas properties in the Midwest. NCI was the surviving entity and was traded on the NASDAQ small cap market as MSIX.

In 1986, the gold mining industry had begun to expand with the introduction of cyanide heap leaching to recover finely disseminated gold. NCI began a project to develop, manufacture and provide sodium cyanide to the new gold mining industry in Nevada. The technology to synthesize hydrogen cyanide was licensed from Mitsubishi Gas Chemical of Japan and the critical reaction and absorption of hydrogen cyanide into caustic soda was developed by NCI. This then allowed for significantly reduced capital costs per unit of installed capacity and much greater inherent safety in the manufacture of this necessary but hazardous chemical. These developments also led to the strategy of producing a liquid product which can be used "as delivered" to the mine site. Previous applications involved the manufacture of dry, dusty briquettes of sodium cyanide which had to be stored, handled and dissolved with pH adjustments at the mine site before actual use.

Construction of first production plant began in 1988 near Winnemucca, Nevada, which is the center of the gold producing area. The plant was commissioned within 18 months and production began in 1990. The "new liquid" product was introduced into the mining community with satellite communication systems to provide security and to dispatch, track and communicate with the tank truck fleet in real time. The concept employed with the manufacture and delivery of product was based on designing a facility and delivery system with redundant safety systems and simplicity. By mid 1992, Degussa joined Cyanco as our 50/50 partner.

In 1995, Cyanco began to de-bottleneck the plant to service the growing demand for its products. The original plant capacity of 28 million pounds was doubled through process improvements and supercharging the plant by the addition of oxygen. In 1998, Cyanco had expanded the plant again, increasing capacity to 85 million pounds per year. These efforts were spearheaded by NCI. This expansion not only provided requisite reliability but also made the facility world scale.

NCI continued to enjoy increasing incomes through 1998 from both the explosives division and Cyanco, but the price of gold in the market was trending downward into ranges which were unprofitable to the marginal gold producers, thereby reducing demand for cyanide. In general, mining and the supply of explosives had become more competitive.

In 2001, NCI sold the explosives division as the market had changed dramatically with the consolidation of several global explosive companies. Over the years the explosives division had expanded with sales approaching $45 million including joint ventures with bulk and packaged products as well as services. Cyanco continues to enjoy the increasing income stream which began in early 1992. This transaction left the "New" Nevada Chemicals, Inc. with a strong balance sheet and retention of the crown jewel of its portfolio, its interest in Cyanco.

In 2002, FMC Corporation, the only other manufacturer of cyanide in the West, decided to exit the sodium cyanide market as Cyanco purchased FMC's sales business and some distribution assets. Over the years Cyanco has become the largest supplier of cyanide in Nevada, remaining profitable even in the face of major mine consolidations, closures, excess cyanide capacity, increasing raw material prices and falling cyanide prices. With the exit of FMC from the market there are now two producers providing sodium cyanide to the market. This new business will improve efficiencies and allow Cyanco to run at higher throughput levels.

We at Nevada Chemicals are excited as we look to the future and our position in this industry segment. The recent rise in gold prices and the renewed interest in gold mining projects bode well for our future.

About Cyanide and Gold Mining

This chart illustrates the general steps in open-pit gold mining. The specifics of the process vary from mine to mine.

 

Investor Relations


Financial Reports


8-K Announcement of Merger Agreement, Nevada Chemicals, Inc. September 5, 2008

10-Q 2nd Quarter Earnings Nevada Chemicals 2008

8-K Announcement of Plant Expansion, Nevada Chemicals, Inc. June 13, 2008

10-Q 1st Quarter Earnings Nevada Chemicals 2008

 

Contact


Nevada Chemicals Inc.
9149 South Monroe Plaza Way
Suite B
Sandy, UT 84070
United States - Map
Phone: 801-984-0228
Fax: 801-984-0231
Web Site: http://www.nevadachemicals.com



 
 

 

PICK: 10/20/08..........CLOSE:.6.43.......SUGGESTED STOP: 11.66


Click here for BMP Sunstone Corporation Homepage

BMP Sunstone Corporation (Nasdaq: NCEM) BMP Sunstone is a Delaware Corporation with Chinese subsidiaries. We are able to offer an end-to-end solution to western pharmaceutical companies interested in selling their products into the Chinese marketplace.

Services we offer include:

  • Pre-market entry analysis
  • Clinical trial management
  • Pre-registration and registration of pharmaceuticals for sale in the People's Republic of China
  • Market research
  • Pharmaceutical marketing to physicians, hospitals, and other healthcare providers
  • Pharmaceutical distribution to hospitals

    In December 2004, Beijing Med-Pharm signed an agreement to purchase Beijing Wanwei Pharmaceutical Corporation, Ltd., a pharmaceutical distributor covering the bulk of Beijing's hospitals.

    This was a historic event, the first-ever purchase of a Chinese pharmaceutical distribution company by a foreign entity, permitted only after a December 2004 change in Chinese law.

    By adding this distributor to our already-existing sales and marketing services, BMP Sunstone hopes to offer an unparalleled opportunity to reach China, the world's fastest-growing market. And our veteran pharmaceutical management staff makes it simple for you to do so.

 

 

Management

 

Mr. David (Xiaoying) Gao, Chief Executive Officer

Mr. Gao has served as BMP Sunstone’s Chief Executive Officer and one of our directors since February 2004. Previously he served as President and Chief Executive Officer of Abacus Investments, Ltd., a private wealth management company, from 2003 to 2004. From 1989 to 2002, Mr. Gao held various senior posts at Motorola including Vice President and Director, Integrated Electronic System Sector, Asia-Pacific operation; Motorola Asia Pacific Management Board, Management Board of Motorola Japan Ltd. and Motorola China Management Board.

Mr. Gao holds a BSC in Mechanical Engineering from the Beijing Institute of Technology, a BSC in Mechanical Engineering from Hanover University, Germany, and an M.B.A. from The Massachusetts Institute of Technology.

 

Mr. Zhiqiang Han, President

Mr. Han has served as BMP Sunstone’s President of China Operations and one of our directors since February 2008. Mr. Han is the founder of Sunstone (Tangshan) Pharmaceutical Corporation, Ltd. and served as Chairman and General Manager since 1996. From 1993 until1996, Mr. Han served as Managing Director of Tangshan Changrong Pharmaceuticals. Previously, Mr. Han was the Chief EngineerLogistic Dept Head/Assistant to the Plant Director in Tangshan Women and Children Pharmaceutical Manufacturer. Mr. Han serves as Vice President of China Nonprescription Medicine Association; Chairman of Heibei Industry and Economic Union; and Vice President of Hebei Pharmaceutical Industry Association.

Mr. Han has a Bachelor of Science degree from Shenyang Pharmaceutical University and an MBA from Dalian University of Technology.

 

Fred Powell, Chief Finance Officer

Mr. Powell has served as BMP Sunstone’s Chief Financial Officer since January 2005. And prior to this, he had been with Eximias Pharmaceutical Corporation as the CFO since May 2002. He was Senior Vice President, Finance and Administration, at InnaPhase where he was mainly responsible for all financial, internal control, HR, administrative, and legal affairs. At Premier Research Worldwide (PRWW), Mr. Powell served as CFO and helped PRWW become one of the nation’s leading clinical research organizations by leading the Company’s initial public offering and managing several acquisitions, including DLB, a clinical trial and data management software company.

From 1983 to 1989, Mr. Powell spent seven years at KPMG Peat Marwick as a Senior Manager responsible for directing the planning, coordination and deliver of audit management and technology services to clients in the pharmaceutical and services industries.

Mr. Powell graduated from Penn State University in 1983, with a Bachelor of Sciences in Accounting and is a Certified Public Accountant.

 

Ms. Yanping Zhao, Vice President

Ms. Zhao has served as BMP Sunstone’s Corporate Vice President since October 2007. From 1992 until 2007, Ms. Zhao held various senior positions with Sino Biopharmaceutical Ltd, where she held senior posts of Vice President and Executive Director in the Corporation, Executive Director in Shandong Chia Tai Freda Pharmaceutical Ltd, as well as Managing Director of its subsidiaries. Ms. Zhao also served as Department Head at Inner Mongolia Medicine and Health Products Import Export Corporation, and Deputy Plan Manager at Inner Mongolia Yuanbaoshan Pharmaceutical Ltd during 1983 to 1992.

Ms. Zhao has a Pharmaceutical degree from Shenyang Pharmaceutical University and a MBA from Dalian University of Technology.


Product Utilizing Our Services

BMP Sunstone is building a proprietary portfolio of branded pharmaceuticals that the company is marketing and distributing in China. Currently, this portfolio includes:

  • Propess®: a vaginal insert used for cervical dilation when labor is induced
  • Anpo (ritodrine hydrochloride): a muscle relaxant, available in both injectable and oral forms, used for managing pre-term labor

 

Corporate Snapshot

Corporate Profile

BMP Sunstone is a Delaware Corporation incorporated in 2003.

Headquartered in suburban Philadelphia, Pennsylvania, and with operations throughout the Peoples Republic of China, BMP Sunstone is focused on becoming the premier development, marketing, and distribution partner for Western manufacturers seeking to introduce high value pharmaceuticals into the large and growing Chinese marketplace.

Complementing seasoned development, sales and marketing teams, BMP Sunstone is building a unique, proprietary network of regional distributors that will allow the Company to reach major Chinese cities comprising the majority of demand for Western medicines. BMP Sunstone is also in-licensing a growing portfolio of branded pharmaceutical products that it will market exclusively across China.

BMP Sunstone offers the following services in China: pre-market entry analysis; clinical trial management; product registration; market research; pharmaceutical distribution to hospitals; and pharmaceutical marketing to physicians, hospitals and other healthcare providers.

 

Recent News